摘要
目的比较齐拉西酮与利培酮治疗精神分裂症的疗效和安全性。方法将76例精神分裂症患者随机分为两组,分别给予齐拉西酮和利培酮治疗8周,采用阳性和阴性症状量表(PANSS)和副反应量表量表(TESS)评定疗效和不良反应。结果齐拉西酮组有效率为84.2%,利培酮组有效率为86.8%,两组疗效差异无统计学意义(P>0.05)。利培酮组内分泌方面不良反应比例明显高于齐拉西酮组。结论齐拉西酮和利培酮疗效相当,但不良反应有所不同。
Objective To compare the efficacy and safety of ziprasidone and resperidone in the treatment of schizophrenia patients. Methods 76 schizophrenics were randomly divided into ziprasdone （ n = 38 ） and resperidone group （ n = 38 ）. The clinical therapeatic effectiveness and side effects were assessed with the positive and negative symptom scales（ PAN- SS ）, and treatment emergent symptom scale （TESS） before treatment and at ends of the 2nd, 4th,6th and 8th,week of treat- ment, respectively. Results There was no significant difference in efficacy between two groups, ziprasidone had less effect than resperidone. Conclusion It is suggested that ziprasidone is effective for schizophrenia, with light side effect.
出处
《中国医学创新》
CAS
2011年第34期19-20,共2页
Medical Innovation of China
